Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable Non-small Cell Lung Cancer
To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for resectable NSCLC patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed previously untreated non-small cell lung cancer.
- Patients with resectable stage II, IIIA and IIIB (N2) disease (according to AJCC 8th edition);
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1;
- 18 years ≤ Age ≤ 80 years;
- Patients with appropriate treatment compliance and could be followed-up correctly;
- Patients with measurable or evaluable diseases (according to RECIST 1.1);
- Patients must have the ability to swallow oral drugs;
- Patients with adequate pulmonary function capable of tolerating the proposed lung resection according to the evidence-based clinical practice guidelines of American College of Chest Physicians;
- Signed and dated written informed consent must be provided by the patient prior to admission to the study.
Exclusion Criteria:
- Subjects with known ALK translocations or EGFR mutations.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease;
- Patients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included;
- Patients with other active malignant tumors currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug;
- Patients who are unable to follow the procedures required in the protocol due to any medical, mental or psychological conditions;
- Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody or any other antibodies or drugs that target T cell costimulation or immune checkpoint pathways;
- Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid indicating acute or chronic infection;
- Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome;
- Patients with a history of allergy to study drugs or ingredients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day) |
3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pathological complete response
Time Frame: After surgery, based on surgical resection specimens and blinded independent pathological review.
|
The percentage of participants with 0% residual viable tumor cells in the primary tumor and sampled lymph nodes after neoadjuvant therapy. |
After surgery, based on surgical resection specimens and blinded independent pathological review.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate
Time Frame: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
The percentage of participants who achieved complete response or partial response after 3 cycles of neoadjuvant therapy according to the RECIST 1.1 criteria. |
21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
|
Clinical TNM downstaging
Time Frame: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
Participants who achieve a a reduction in the corresponding radiological T, N, or overall TNM stage compared with baseline. |
21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
|
|
Treatment-related Adverse Events
Time Frame: Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
|
The number of participants with treatment-related adverse events as assessed by CTCAE v5.0. |
Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
|
|
Disease free survival
Time Frame: 1 year, 3 years and 5 years after the operation
|
The time (month) from the completion of lung cancer radical surgery to the recurrence or metastasis of the disease. |
1 year, 3 years and 5 years after the operation
|
|
Recurrence rate
Time Frame: 1 year, 3 years and 5 years after the operation
|
The percentage of participants who have recurrence or metastasis of lung cancer at certain time points after radical surgery. |
1 year, 3 years and 5 years after the operation
|
|
Overall survival
Time Frame: 1 year, 3 years and 5 years after the operation
|
The time (month) from the completion of lung cancer radical surgery to all-cause death. |
1 year, 3 years and 5 years after the operation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yang Gao, Doctor, Xiangya Hospital of Central South University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Organic Chemicals
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Dietary Supplements
- Food
- Diet, Food, and Nutrition
- Physiological Phenomena
- Food and Beverages
- Taxoids
- Cyclodecanes
- Diterpenes
- Genome Components
- Genome
- Genetic Structures
- Genetic Phenomena
- Molecular Structure
- Biochemical Phenomena
- Chemical Phenomena
- Retroelements
- Interspersed Repetitive Sequences
- Repetitive Sequences, Nucleic Acid
- Base Sequence
- Paclitaxel
- Probiotics
- Short Interspersed Nucleotide Elements
Other Study ID Numbers
Other Study ID Numbers
- 202007093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
all IPD that underlie results in a publication
IPD Sharing Time Frame
IPD will be shared when the clinical trail is finished
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.